The partners added non-human indications to a 2005 deal that granted Spectrum exclusive, worldwide rights to develop and commercialize Altair's RenaZorb family of compounds for all human indications. The oral lanthanum-based phosphate binding compound is...

Altair Nanotechnologies Inc. (NASDAQ:ALTI), Reno, Nev.   Business: Drug delivery, Supply/Service   Transitioned: Terry Copeland to president and CEO, from interim president  ...

Altair Nanotechnologies Inc. (NASDAQ:ALTI), Reno, Nev.   Business: Drug delivery, Supply/Service   Appointed: Robert van Schoonenberg, EVP, chief legal officer and secretary at Avery Dennison Corp.  ...

Altair Nanotechnologies Inc. (NASDAQ:ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Transitioned: Terry Copeland to interim president, while remaining VP of operations at Altair's power and energy group; he replaces President and CEO Alan...

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Hired: Jeffrey McKinney as VP and chief patent counsel, formerly special counsel at Sheppard Mullin Richter & Hampton LLP  ...

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Appointed: Andrew Burke  ...

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Chemistry   Appointed: John Midgley, CEO of Ultradots Inc.  ...

The companies resolved their arbitration related to milestone payments under a 2005 deal in which SPPI received exclusive worldwide rights to develop and market ALTI's RenaZorb lanthanum-based phosphate binding compound for kidney disorders (see BioCentury,...

Altair Nanotechnologies Inc. (ALTI), Reno, Nev.   Business: Drug delivery, Renal   Departed: Rudi Moerck as president  ...

Spectrum received exclusive worldwide rights develop and market ALTI's RenaZorb . The lanthanum-based phosphate binding compound is in preclinical development to control phosphate levels in patients with chronic kidney disease (CKD) and hyperphosphatemia associated with end...